DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Garon EB, Ciuleanu TE, Arrieta O et al.
Ramucirumab plus docetaxel vs. placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Lancet 2014;
384: 665-673
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.